Enjoy complimentary customisation on priority with our Enterprise License!
The thrombosis drugs market size is forecast to increase by USD 17.02 billion at a CAGR of 10.03% between 2023 and 2028. The market is experiencing significant growth, driven by the introduction of novel oral anticoagulants (NOACs) that offer improved efficacy and reduced side effects compared to traditional anticoagulants. NOACs have gained popularity due to their convenience and ease of use, leading to a shift from injectable anticoagulants. Another growth factor is the rising prevalence of sedentary lifestyles and obesity, which increase the risk of thrombosis. Thrombotic disorders, including deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, and others, are major health concerns worldwide. However, the market faces challenges, including the strong side effects of anticoagulants, such as bleeding risks, and the high cost of these pharmaceutical equipment and medications. Regulatory approvals and reimbursement policies also impact market growth. In summary, the market is witnessing robust growth due to the introduction of NOACs and increasing prevalence of thrombosis risk factors, but faces challenges related to side effects and cost.
The Market is driven by the increasing prevalence of thrombotic disorders, particularly in the geriatric population and those undergoing surgical procedures. Factors such as sedentary lifestyles, obesity, chronic conditions like diabetes, cardiovascular disease, and infectious diseases contribute to the rising incidence of these disorders. Thrombosis medications, including antiplatelet drugs, thrombolytic drugs, and novel oral anticoagulants, play a crucial role in treatment and prevention. The aging population, with its higher susceptibility to thrombotic disorders, is a significant market opportunity. Drug development in this area is ongoing, with a focus on personalized medicine, drug delivery systems, outpatient management, home healthcare, long-acting formulations, transdermal patches, and implantable devices. The regulatory framework for thrombosis drugs is stringent, ensuring safety and efficacy. The pipeline analysis of thrombosis drugs is robust, with several promising candidates in various stages of development. The market is expected to grow significantly due to the increasing healthcare expenditure and the rising obesity rates.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The pulmonary embolism segment is estimated to witness significant growth during the forecast period. The Market encompasses the development and distribution of medications used for the treatment and prevention of thrombotic disorders, including deep vein thrombosis, pulmonary embolism, heart attacks, stroke, myocardial infarction, and venous thromboembolism. With an aging population and rising prevalence of sedentary lifestyles, obesity, chronic conditions such as diabetes, and cardiovascular diseases, the demand for thrombosis medications continues to escalate.
Get a glance at the market share of various regions Download the PDF Sample
The pulmonary embolism segment was the largest segment and valued at USD 12.93 billion in 2018. Thrombosis medications include anticoagulants, antiplatelet drugs, thrombolytic drugs, novel oral anticoagulants, and various drug delivery systems. Personalized medicine and advancements in diagnostic imaging techniques and laboratory assays are driving innovation in the market. Thrombosis medications are administered through various routes, including oral medications, self-administered injectables, and implantable devices. Hospital pharmacies and outpatient management, as well as home healthcare, are key distribution channels. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Thrombotic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, and venous thromboembolism (VTE), pose significant health risks, particularly among the geriatric population and those undergoing surgical procedures. The rising prevalence of sedentary lifestyles, obesity, chronic conditions such as diabetes and cardiovascular diseases, and an aging population have fueled the demand for thrombosis medications. Drug development in this area focuses on anticoagulants, antiplatelet drugs, thrombolytic drugs, novel oral anticoagulants, and personalized medicine. Hence, such factors are driving the market in North America during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Introduction of novel oral anticoagulants is notably driving market growth. The market has witnessed significant advancements in recent years, with a focus on developing oral anticoagulants to improve patient adherence. Early anticoagulants, primarily administered via the parenteral route, faced challenges in patient acceptance due to their non-friendly nature and poor patient compliance.
Moreover, in response, market players introduced novel oral anticoagulants, such as direct thrombin inhibitors like dabigatran and anti-Xa agents including ELIQUIS (apixaban), SAVAYSA, LIXIANA (edoxaban), and XARELTO (rivaroxaban). These new-generation oral anticoagulants have gained popularity among medical professionals and patients, driving market growth during the forecast period.
Sedentary lifestyle is the key trend in the market. Thrombosis, a condition characterized by the formation of blood clots in the arteries or veins, is a significant health concern worldwide. Obesity and advanced age are leading risk factors for thrombosis, with obesity being a result of both genetic and environmental factors. A sedentary lifestyle, characterized by little to no physical activity, is a major contributor to obesity and the subsequent risk of thrombosis. Deep Vein Thrombosis (DVT), a type of thrombosis, can occur when the muscles in the legs do not contract, preventing proper blood flow.
Moreover, this can lead to the formation of blood clots in deep veins. The global market is witnessing significant growth due to the increasing prevalence of thrombosis, particularly in the context of cancer-related thrombosis, pulmonary embolism, and atrial fibrillation. Key players in the market include Bayer and Anthos Therapeutics, with the latter developing Abelacimab, an antiplasmin antibody for thrombosis treatment. Thus, such trends will shape the growth of the market during the forecast period.
Strong side-effects of anticoagulants is the major challenge that affects the growth of the market. Thrombosis drugs, also known as anticoagulants or blood thinners, are essential medications used to prevent and treat various types of blood clots in the body. These drugs hinder the clotting process, allowing the blood to flow freely.
However, their use comes with potential side effects, including increased risk of bleeding, especially in cases of injuries. Bayer AG and Anthos Therapeutics are among the global brands developing thrombosis drugs, such as antiplasmin antibody and Abelacimab, respectively. Thrombosis affects various patient populations, including those with Cancer-related thrombosis, Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aspen Pharmacare Holdings Ltd: The company offers the thrombosis portfolio which is comprised largely of a broad range of specialist injectable anticoagulants.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Thrombotic Disorders market is witnessing significant growth due to the increasing prevalence of thrombotic disorders, especially among the geriatric population and those undergoing surgical procedures. Thrombotic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, and venous thromboembolism (VTE), are major health concerns, particularly in sedentary lifestyles, obesity, chronic conditions like diabetes, and cardiovascular diseases. The thrombosis medications market comprises anticoagulants, antiplatelet drugs, thrombolytic drugs, novel oral anticoagulants, and various drug delivery systems. Anticoagulants and antiplatelet drugs are the most commonly used classes for the treatment and prevention of thrombotic disorders. Factor Xa inhibitors and direct thrombin inhibitors are novel oral anticoagulants gaining popularity due to their effectiveness and ease of administration. Personalized medicine and advanced drug delivery systems, such as long-acting formulations, transdermal patches, implantable devices, oral anticoagulants, and self-administered injectables, are transforming the market. Outpatient management and home healthcare are emerging trends in the market, offering cost-effective solutions for patients. Diagnostic imaging techniques and laboratory assays play a crucial role in the diagnosis and monitoring of thrombotic disorders. The aging population, healthcare expenditures, and label extensions for thrombosis medications are key factors driving the growth of the market. The route of administration and oral medications are the most common methods for administering thrombosis drugs, with hospital pharmacies being the primary point of sale. Overall, the market is expected to continue its growth trajectory, offering ample opportunities for market participants.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
144 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
|
Market growth 2024-2028 |
USD 17.02 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.88 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, France, Norway, UK, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Aspen Pharmacare Holdings Ltd., AuroMedics Pharma LLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, GoodRx Holdings Inc., Grifols SA, Inari Medical Inc., Italfarmaco Holding SPA, Johnson and Johnson Services Inc., Pfizer Inc., Sanofi SA, Vasudha Pharma Chem Ltd., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, market report , market forecast , Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Indication
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.